CRSP presents Phase 1a CTX310 data at ESC Congress 2026
CRISPR Therapeutics presented Phase 1a data for CTX310 at ESC Congress 2026, including ANGPTL3 editing and triglyceride and LDL lowering.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.